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Abstract
Background: Autoantibodies against monomeric C-reactive protein (anti-CRP-Ab) observed in patients with
systemic lupus erythematosus (SLE) and lupus nephritis (LN) were suggested to be associated with active LN and a
poor response to therapy during short-term follow-up.
The aim of this study was to confirm this finding and to investigate the prognostic value of anti-CRP-Ab in patients
with LN during long-term follow-up.
Methods: Sera of 57 SLE patients (47 women, 10 men) with biopsy proven LN and 122 healthy individuals were
analyzed for the presence of anti-CRP-Ab by in-house ELISA.
Anti-CRP-Ab levels were studied in relation to routine laboratory tests, urine analysis, levels of C3, C4, other immunological
markers and the overall disease activity as assessed by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).
The prognostic value of anti-CRP-Ab was tested in a subgroup of 29 newly diagnosed LN patients (median follow-up
5.9 years). Response to therapy at various time points was assessed with respect to baseline anti-CRP-Ab levels. At least
partial response in the first/second year of treatment was considered as a “favorable outcome”, while non-response, renal
flare or end stage renal disease were considered as “unfavorable outcome”.
Results: Anti-CRP-Ab were only detected in patients with active renal disease and their levels correlated with
SLEDAI (rs = 0.165, p = 0.002). The time to response was shorter in patients being anti-CRP-Ab negative at baseline
compared to anti-CRP-Ab positive patients, p = 0.037. In the second year of therapy, baseline anti-CRP-Ab positivity was
a significant predictor of “unfavorable outcome” (OR [95 % CI] = 15.6 [1.2-771]; p = 0.021). The predictive value of
“baseline anti-CRP positivity” further increased when combined with “non-response to therapy in the first year”.
Baseline anti-CRP-Ab positivity was not a predictor of “unfavorable outcome” at the end of follow-up, (OR [95 % CI] =
5.5 [0.6-71.1], p = 0.169).
Conclusions: Baseline serum levels of anti-CRP-Ab seem to be a strong risk factor for a composite outcome of
non-response, renal flare or end stage renal disease after two years of standard treatment of LN. The response to
therapy seems to be delayed in anti-CRP-Ab positive patients.
Background
Systemic lupus erythematosus (SLE) is a complex auto-
immune disease leading to the formation of a wide range
of pathogenic autoantibodies and immune complexes.
SLE mainly affects young women, with a clinically
significant impact on morbidity and mortality. Renal in-
volvement is among the most severe manifestations of
SLE, which in its most aggressive forms can lead to renal
failure.
The pathogenesis of SLE is only partially understood.
A number of potentially pathogenic autoantibodies have
been described in SLE; for example, anti-double-stranded
DNA antibodies (anti-dsDNA-Ab), anti-nucleosome anti-
bodies, and anti-C1q antibodies (anti-C1q-Ab). Some of
these correlate with SLE and/or lupus nephritis (LN)
activity and are used in routine clinical practice for
diagnostic purposes [1–7].
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Pentameric C-reactive protein (CRP) under specific condi-
tions dissociates irreversibly into monomers (mCRP) and
reveals new epitopes [8–11]. The physiological function of
mCRP includes opsonization, elimination of immune com-
plexes, and clearance of apoptotic cells. This is achieved by the
interaction of mCRP with C1q and complement factor H [12].
While other acute phase proteins increase in active SLE,
levels of CRP usually remain low [13]. This might be
caused by a suppression of interleukin (IL)-6-mediated
CRP production in hepatocytes by overexpression of inter-
feron alpha (IFNα) [14] and by CRP gene polymorphisms
[15]. Another mechanism could be an accelerated conver-
sion of CRP into mCRP [16].
Antibodies interfering with the function of mCRP (such
as IgG autoantibodies against mCRP (anti-CRP-Ab)) might
lead to an altered clearance of apoptotic cells and be in-
volved in pathogenic mechanisms of LN [12]. Interestingly,
anti-CRP-Ab recognize the mCRP subunits, but not the na-
tive pentameric form of CRP, and thus—as other lupus
autoantibodies—can be considered neo-epitope specific [8].
A high prevalence of anti-CRP-Ab in SLE patients was
described by Bell et al. [8]. Later, anti-CRP-Ab were shown
to be associated with active LN [17–19] and renal tubu-
lointerstitial lesions [18]. Some authors observed colocali-
zation of IgG with CRP and other factors such as C1q and
anti-dsDNA-Ab in the glomerular basement membrane
and the renal subendothelial space in LN [20, 21]. Another
study showed that levels of anti-CRP-Ab correlated with
the renal biopsy activity index, as documented on repeated
renal biopsies, and predicted a poor response to therapy
during an 8-month follow-up [17].
The aim of our study was to determine whether
baseline anti-CRP-Ab positivity predicts the long-term
outcome in LN patients treated with standard therapy.
Methods
Study subjects
A total of 57 patients (47 women, 10 men; median age
32.1 years) with definite SLE classified according to the
American College of Rheumatology criteria [22] and biopsy-
proven LN (29 new diagnoses of LN in 2005–2010, 28
previous diagnoses) were recruited into the study at the
Department of Nephrology, General University Hospital,
Prague, Czech Republic between 2005 and 2010. Basic
patient characteristics are presented in Table 1. Renal
biopsies were scored according to the classification of
the International Society of Nephrology and the Renal
Pathology Society in 2003 [23]. One hundred and nineteen
serum samples from these patients at different time points
of the disease were obtained. For comparisons of anti-
CRP-Ab serum levels with those of the control group,
and to correlate these levels with disease activity and
other parameters, only one serum sample per patient was
randomly selected.
To assess the role of baseline anti-CRP-Ab levels in
the prediction of therapeutic outcome during long-term
follow-up, only patients with newly diagnosed active LN
(as proven by renal biopsy) were included (n = 29). Base-
line serum samples were taken at the time of biopsy.
One hundred and twenty-two serum samples from
age-matched healthy volunteers served as controls.
Ethics
The study protocol was approved by the Ethics Commit-
tee of the General University Hospital, Prague (2087/10
A, D; basic study 706/04 S) and made to conform to the
ethical guidelines of the latest Declaration of Helsinki.
Informed consent was obtained from all subjects.
Definitions
Global disease activity was assessed by the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) [24]. In this
study, active LN was defined as active urinary sediment,
and/or proteinuria ≥0.5 g/day, and/or worsened glomerular
filtration rate (GFR) >25 % above baseline/normal range
caused by active LN, and/or C3 hypocomplementemia while
any other causes were excluded. At least two of the afore-
mentioned criteria had to be met.
Response to therapy at follow-up was assessed accord-
ing to European consensus criteria [25].
Complete response was defined as inactive urinary sedi-
ment, decrease of proteinuria to ≤0.2 g/day, and normal/
stable renal function (<10 % of normal GFR). Partial re-
sponse was defined as inactive urinary sediment, protein-
uria ≤0.5 g/day, and normal/stable renal function (<10 %
from baseline levels if abnormal).
At least partial response in the first/second year of treat-
ment was considered a “favorable outcome”, while nonre-
sponse, renal flare, or end-stage renal disease (ESRD) was
considered an “unfavorable outcome”.
Renal flare was defined as an increase of disease activity
requiring more intensive therapy (addition/change of im-
munosuppressive therapy, or administration of high-dose
pulses of corticosteroids).
Table 1 Basic characteristics of the patients
Age (years) 32 (21.7–62.4)
Gender, male/female 10/47
Caucasian/Asian 55 (96.5 %)/ 2 (3.5 %)
Renal disease duration (days) 75 (1–2413)
Renal biopsy Class II 2 (3.5 %)
Class III 13 (22.8 %)
Class IV 28 (49.1 %)
Class III/V or IV/V 11 (19.3 %)
Undetermined class 3 (5.3 %)
Data presented as median (5th and 95th percentile) or number of patients (%)
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Biochemical analyses
At the time of blood sampling, routine laboratory tests in all
patients were performed in the laboratories of the Institute
of Medical Biochemistry and Laboratory Diagnostics of the
General University Hospital, Prague, including measure-
ments of 24-hour proteinuria, GFR, urinary sediment ana-
lyses, complement C3 and C4, and anti-dsDNA-Ab. Further
analyses were carried out subsequently from sera stored at
−80 °C. Serum amyloid A (SAA) was determined by a com-
mercial enzyme-linked immunosorbent assay (ELISA) kit
(Invitrogen, Carlsbad, CA, USA), high-sensitivity CRP
(hsCRP) was measured by particle-enhanced immunone-
phelometry (Behring Nephelometer II; Siemens, Munich,
Germany), and anti-C1q-Ab were measured by ELISA
(Bühlmann Laboratories, Switzerland. Schönenbuch).
Anti-CRP-Ab assay
Levels of anti-CRP-Ab were measured by in-house ELISA
according to Sjöwall et al. [26] with slight modifications.
One hundred microliters of human native CRP (Sigma, St.
Louis, MO, USA) diluted with carbonate/bicarbonate buf-
fer (50 mM, pH 9.6) to a concentration of 1 mg/l was
added to each well of a Maxisorp microtiter plate (Nunc,
Denmark, Roskilde) and incubated overnight at room
temperature. After washing four times with phosphate-
buffered saline (PBS, pH 7.4) with 0.05 % Tween 20
(Sigma), coated plates were incubated (1 hour, room
temperature) with 100 μl serum samples diluted 1:20
with PBS–Tween. After an additional four-times wash
with PBS–Tween, 100 μl alkaline phosphatase-conjugated
rabbit IgG antibodies raised against human γ-chains
(DAKO, Denmark, Glostrup) was added (diluted 1:500 in
PBS–Tween). After 1 hour of incubation, plates were
washed four times with PBS–Tween and 100 μl p-ni-
trophenyl phosphate (10 g/l; Sigma) diluted in the re-
action buffer (carbonate/bicarbonate buffer, 50 mM,
pH 9.6; 1 mM MgCl2) was added. After 1 hour of incuba-
tion (room temperature, dark), the reaction was stopped
by addition of 25 μl of 3 M NaOH. Absorbances were read
at 405 nm. All samples were analyzed in quadruplicate. A
calibration curve was constructed by serial dilution of the
most positive sample with the negative one. Results were
expressed as arbitrary units (AU), which are defined as a
percentage of the highest patient sample. The cutoff value
for a positive test (45.5 AU) was set as the 95th percentile in
122 healthy individuals. The limit of detection was 15 AU.
Statistical analyses
Owing to the skewed data distribution, nonparametric
tests were used. Results are presented as the median plus
5th and 95th percentiles, numbers (%), or odds ratio
(OR) and 95 % confidential interval (95 % CI). The pre-
dictive value of two risk factors (baseline anti-CRP-Ab
positivity and nonresponse in the first year) was assessed
using logistic regression. To prevent model overadjust-
ment (the small number of subjects enabled us to reli-
ably analyze only one predictor), both predictors were
combined to form a single risk factor. Because they have
similar ORs, both predictors were considered equipotent
and were used unweighted.
Furthermore, the Mann–Whitney rank sum test,
Kruskal–Wallis analysis of variance and Spearman’s correl-
ation coefficient (rs) were calculated and Kaplan–Meier sur-
vival curves were constructed using STATISTICA software
(version 9; StatSoft Inc., Tulsa, OK, USA). Differences
between survival curves were tested by the Mantel–Cox
test. Fisher’s exact test, the chi-square test, and logistic
regression were calculated using EpiInfo (version 3.5.3;
Centers for Disease Control and Prevention, Atlanta,
GA, USA). For calculations, an arbitrary anti-CRP-Ab
concentration of 7.5 AU was assigned to each sample
that was below the limit of detection (15 AU).
Results
Prevalence of anti-CRP-Ab and their relationship to SLE
activity
Levels of anti-CRP-Ab were significantly higher in LN
patients compared with healthy controls (21.1 AU
(<15.0–98.6) vs. <15.0 AU (<15.0–45.5), respectively; p =
0.012). Over one-quarter (26.3 %) of SLE patients was
considered to be anti-CRP-Ab-positive (i.e., the concen-
tration exceeded the threshold value of 45.5 AU). Anti-
CRP-Ab positivity was exclusively observed in patients
with active LN 15/46 (33 %), while it did not occur in
patients with inactive renal disease (0/11, p = 0.051). In
addition, levels of anti-CRP-Ab were significantly higher
in patients with active LN than in patients with inactive
LN (26.8 AU (<15.0–89.4) vs. <15.0 AU (<15.0–30.6);
p = 0.009) and correlated with the overall activity of
SLE as assessed by the SLEDAI (rs = 0.41, p = 0.002).
Anti-CRP-Ab association with established immunological
markers of LN
A significant negative correlation was found between
levels of anti-CRP-Ab and complement C3 (rs = − 0.509,
p < 0.0001), but not complement C4. Additionally, anti-
dsDNA-Ab-positive patients had significantly higher levels
of anti-CRP-Ab as compared with anti-dsDNA-Ab-
negative patients (31.6 AU (<15.0–91.6) vs. <15.0 AU
(<15.0–57.8); p = 0.007). However, the levels of anti-
CRP-Ab did not correlate with anti-C1q-Ab (rs = 0.127,
p <0.353).
There was also no association between anti-CRP-Ab
levels and the acute phase proteins SAA and hsCRP.
Clinical follow-up
Twenty-nine patients with newly diagnosed active LN were
followed for a median of 5.9 (3.9–7.4) years. A baseline
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comparison of anti-CRP-Ab-positive and anti-CRP-Ab-
negative patients is summarized in Additional file 1.
During follow-up, one patient died, two were lost from
follow-up, and two patients were excluded because of
noncompliance to therapy. Additionally, one patient’s data
could not be analyzed because he did not fulfill criteria
either for “favorable” or for “unfavorable” at year 2. Data
from 26 patients were available at year 1, while we ob-
tained data from 25 patients at year 2. Data from 23 pa-
tients were available for analysis at the end of follow-up
(March 2014). An overview of induction and mainten-
ance therapy is presented in Additional file 1.
Most interestingly, the time to response was significantly
shorter in baseline anti-CRP-Ab-negative patients than in
those anti-CRP-Ab-positive (p = 0.037) (Fig. 1). In addition,
after having reached partial/complete response, the time to
flare tended to be shorter in anti-CRP-Ab-positive than in
anti-CRP-Ab-negative patients, although this difference did
not reach statistical significance (p = 0.075) (Fig. 2).
During the long-term follow-up period, 5/10 (50 %) of
baseline anti-CRP-Ab-positive patients experienced at least
one flare after previous response, while only 2/13 patients
(15.4 %) had renal flare in the other group. This difference,
however, was not significant, most likely due to the
low number of patients involved (OR (95 % CI) = 5.5
(0.6–71.1), p = 0.169).
Predictive value of anti-CRP-Ab
After the first year of therapy, 6/11 (54.5 %) baseline
anti-CRP-Ab-positive patients and 6/15 (40 %) anti-
CRP-Ab-negative patients did not respond to therapy
(p = 0.736).
However, at the end of the second year of follow-up,
6/11 (54.5 %) baseline anti-CRP-Ab-positive patients had
“unfavorable outcome” (nonresponse to therapy or renal
flare), while only one patient remained without response
in the baseline anti-CRP-Ab-negative group (9.1 %) (see
Fig. 3). Baseline anti-CRP-Ab positivity was thus a sig-
nificant predictor of “unfavorable outcome” (OR (95 %
CI) = 15.6 (1.2–771); p = 0.021).
As described previously, early response to treatment is
associated with better outcome [27, 28]. This was also
the case in our cohort: patients who did not respond to
therapy in the first year were more likely to exhibit “un-
favorable outcome” in the second year (OR (95 % CI) =
12 (1–596.6); p = 0.03). Because these two predictors
(baseline anti-CRP-Ab positivity and nonresponse in the
first year) seemed to be independent (not correlating),
we tested whether they might have an additive effect.
Our data show that each of the risk factors increased the
risk of “unfavorable outcome” more than 20 times (OR
(95 % CI) = 26.3 (2.2–308.7); p = 0.009) and the OR in
patients having both risk factors would be doubled.
Discussion
The occurrence of anti-CRP-Ab has been described
previously, most often in patients diagnosed with SLE
[8, 18, 19, 29–32]. In our study, we focused on patients
with LN proven by renal biopsy. We found that preva-
lence of anti-CRP-Ab in newly diagnosed active LN was
44.8 % and that anti-CRP-Ab positivity was significantly
Fig. 1 Time to response in anti-CRP-Ab-positive/negative LN patients. Kaplan–Meier survival curves demonstrate faster achievement of response
in baseline anti-CRP-Ab-negative LN patients. Crosses indicate censored patients (i.e. those not responding within the follow-up period or lost
from follow-up; n = 4), while finished patients (i.e. responders; n = 24) are shown as open circles. anti-CRP-Ab anti-C-reactive protein antibodies
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associated with “unfavorable outcome” at 2 years. The
therapeutic response in anti-CRP-Ab-positive patients
was delayed.
Published prevalence of anti-CRP-Ab in patients with SLE
varied between 26 % and 78 % [8, 17–19, 26, 29, 31–36].
Generally, anti-CRP-Ab appear mostly in patients with
active disease, especially in those with renal involve-
ment [17–19]. In our study, approximately one-quarter
of LN patients were anti-CRP-Ab-positive. Because anti-
CRP-Ab positivity was observed exclusively in patients
with active renal disease, it appears that anti-CRP-Ab
could serve as a useful marker of active LN. This is in ac-
cordance with conclusions of Sjöwall et al. [17], who ob-
served a decrease of anti-CRP-Ab in patients with active
renal disease in transition to remission. Additionally, we
can confirm that anti-CRP-Ab levels correlate with the ac-
tivity of SLE [17, 18, 29].
Besides monitoring SLE disease activity, anti-CRP-Ab
might exhibit an even more important role; that is, a pre-
dictive potential as suggested by Sjöwall et al. [17], who re-
ported more than a doubled risk for adverse therapeutic
response in patients with baseline anti-CRP-Ab positivity.
Fig. 2 Time to flare in anti-CRP-Ab-positive/negative LN patients. Kaplan–Meier survival curves demonstrate time to flare in baseline anti-CRP-
Ab-positive/negative LN patients. Crosses indicate censored patients (i.e. those who had not experienced flare within the follow-up period or
those lost from follow-up; n = 18), while finished patients (i.e. patients with flare; n = 6) are shown as open circles. anti-CRP-Ab anti-C-reactive
protein antibodies
Anti-CRP-Ab positive Anti-CRP-Ab negative
First year
Second year
“Favorable“ “Unfavorable“ “Favorable“ “Unfavorable“
CR CRPR PRNR/flare NR/flare
Outcome Outcome
Fig. 3 Response to therapy in anti-CRP-Ab-positive/negative LN patients. Baseline anti-CRP-Ab-positive patients are more likely to exhibit “unfavorable
outcome” after 2 years of therapy, when compared with anti-CRP-Ab-negative patients. anti-CRP-Ab anti-C-reactive protein antibodies, CR complete
response, NR nonresponse, PR partial response
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We could not confirm anti-CRP-Ab as a significant pre-
dictor of “unfavorable therapeutic outcome” after 1 year of
therapy (OR = 1.8; p = 0.368). However, as described previ-
ously, the response to therapy in LN patients is relatively
slow and many patients only achieve remission after the
switch to “maintenance” therapy [37]. We now show
that this may be especially true in anti-CRP-Ab-positive
patients who showed longer time to response than anti-
CRP-Ab-negative patients, which might have potential
therapeutic consequences.
Because of the possible delay of a therapeutic response
in SLE, we assessed the therapeutic response also after
2 years of standard therapy. Additionally, we were moni-
toring the frequency of flares throughout the follow-up
(median 5.9 years).
After 2 years of therapy, during the time of mainten-
ance therapy, baseline anti-CRP-Ab positivity seemed to
be a strong predictor of therapeutic response. Positive
patients faced a more than 10 times higher risk of non-
response when compared with those being anti-CRP-
Ab-negative. Not surprisingly, the therapeutic response
after 2 years of therapy depended on the response in the
first year. Again, patients not responding in the first year
are more likely (more than 10 times) not to respond
during prolonged therapy. The predictors already men-
tioned seem to be independent, each having an additive
effect. Patients carrying both risk factors (anti-CRP-Ab-
positive at baseline, not responding at year 1) are at ap-
proximately 50 times higher risk of treatment failure in
the second year. This strong prediction thus suggests
that in such patients intensification of existing therapies
or an alternative therapeutic approach (e.g. biological
therapy) should be considered.
In the extended follow-up period, anti-CRP-Ab were
not confirmed as a significant predictor of renal flares
(OR = 5; p = 0.092). However, the quite high OR and bor-
derline significance do not allow us to reject anti-CRP-
Ab positivity as a predictor of flares, and an independent
confirmative study recruiting a larger number of patients
with prospective follow-up seems to be needed to draw
a final conclusion.
To the best of our knowledge, this is the first study
assessing the predictive role of anti-CRP-Ab in the long-
term follow-up. The relatively small number of patients
(accompanied by quite low statistical power of used tests)
is probably the major limitation of this study. As a result,
calculated ORs are imprecise (95 % CIs are very wide) and
several interesting findings could not be considered as
being significant. Because of the low frequency of the
disease, a multicenter study seems to be essential. An-
other limiting factor was the unavailability of repeated
renal biopsy samples—the response to therapy (and
activity of LN) was assessed only by means of labora-
tory and clinical investigation. However, repeated renal
biopsies are invasive and not routinely performed to
date.
Conclusion
Our data indicate that anti-CRP-Ab positivity might be a
strong predictor of unfavorable long-term therapeutic
response, which, moreover, seems to be delayed. Base-
line anti-CRP-Ab-positive patients, especially those not
responding to standard therapy within 1 year, seemed not
to benefit from further standard treatment. Nevertheless,
the potential role of the routine use of anti-CRP-Ab meas-
urement for the monitoring and guidance of treatment in
LN patients needs to be confirmed in larger prospective
studies.
Additional file
Additional file 1: is a table presenting baseline characteristics and
laboratory data of patients with newly diagnosed LN. Data presented
as median (5th and 95th percentiles) or number (%), differences compared
using the Mann–Whitney test unless otherwise stated. *Fisher Exact test.
**Expressed as number (%) of patients with erytrocyturia above normal
range. ***χ2, GFR expressed as clearance of creatinine. Anti-CRP-Ab anti-C-
reactive protein antibodies, anti-C1q-Ab anti-C1q antibodies, GFR glomerular
filtration rate, hsCRP high-sensitivity C-reactive protein, NS not significant,
SLEDAI Systemic Lupus Erythematosus Disease Activity Index. (XLS 17 kb)
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